Back to List View Graph View

Glucose-dependent insulinotropic polypeptide (GIP)

Gastric inhibitory polypeptide, more commonly referred to as glucose-dependent insulinotropic polypeptide (GIP), is a gut-derived peptide hormone and protein target involved in the regulation of glucose metabolism.

Where the papers sit

8 papers from the last 6 months study Glucose-dependent insulinotropic polypeptide (GIP) directly · updated from PubMed 9 Nov 2026

Those 8 are all about one subject.

  • GIP-Based Metabolic Therapies

    GIP-based treatment is moving from single-hormone infusion toward dual and triple agonists for obesity and type 2 diabetes. Tirzepatide, semaglutide combinations and retatrutide-related reports emphasize weight regain, glycaemic control and practical safety. Studies repeatedly assess insulin, glucagon and cardiovascular responses during hyperglycaemia, while nausea remains a limiting adverse effect. The clinical roles of native GIP and multi-agonist therapies remain under definition.

    8 papers

Papers

The 8 papers from the last 6 months that study Glucose-dependent insulinotropic polypeptide (GIP) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

GIP-Based Metabolic Therapies (8)
  1. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ case reports · 7 Oct 2026 PMID 42843917
  2. Bone marrow responses to GLP-1 and GIP infusion under hyperglycaemic conditions. European journal of endocrinology · 19 Sept 2026 PMID 42762476
  3. Overview of weight loss medicines and practical advice for patients. Nursing standard (Royal College of Nursing (Great Britain) : 1987) · 1 Sept 2026 PMID 42676263
  4. Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity. Journal of computer-aided molecular design · 30 Jul 2026 PMID 42530676
  5. Effects of Pharmacological GIP Infusion on Insulin, Glucagon, and Cardiovascular Responses During Hyperglycemia in Type 2 Diabetes. Diabetes · 14 Jul 2026 PMID 42447284
  6. The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. Bioscience reports · 17 Jun 2026 PMID 42307179
  7. Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety. Obesity surgery · 5 Jun 2026 PMID 42247124
  8. Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology · 22 May 2026 PMID 42173109

By study type

Clinical trials (2)
  1. Effects of Pharmacological GIP Infusion on Insulin, Glucagon, and Cardiovascular Responses During Hyperglycemia in Type 2 Diabetes. Diabetes · 14 Jul 2026 PMID 42447284
  2. Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology · 22 May 2026 PMID 42173109
Observational studies and case reports (1)
  1. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ case reports · 7 Oct 2026 PMID 42843917
Human data, design not indexed (3)
  1. Bone marrow responses to GLP-1 and GIP infusion under hyperglycaemic conditions. European journal of endocrinology · 19 Sept 2026 PMID 42762476
  2. Overview of weight loss medicines and practical advice for patients. Nursing standard (Royal College of Nursing (Great Britain) : 1987) · 1 Sept 2026 PMID 42676263
  3. Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity. Journal of computer-aided molecular design · 30 Jul 2026 PMID 42530676
Unclassified: not yet indexed with MeSH (2)
  1. The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. Bioscience reports · 17 Jun 2026 PMID 42307179
  2. Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety. Obesity surgery · 5 Jun 2026 PMID 42247124